Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia.

Gupta S, Jen J, Kolz K, Cutler D.

Br J Clin Pharmacol. 2007 Mar;63(3):292-9. Epub 2006 Aug 30.

2.

Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.

Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P.

Cancer. 2002 Jul 15;95(2):389-96. Review.

3.

Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.

Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, Hooftman L, Kantarjian H.

Clin Cancer Res. 2005 Sep 1;11(17):6247-55.

4.

Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction.

Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, Sack M, Glue P, Jacobs S, Affrime M.

J Clin Pharmacol. 2002 Oct;42(10):1109-15.

PMID:
12362925
5.

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S.

Clin Pharmacol Ther. 2000 Nov;68(5):556-67.

PMID:
11103758
6.

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.

Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP.

Hepatology. 2000 Sep;32(3):647-53.

PMID:
10960463
7.

Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.

ter Borg MJ, Hansen BE, Herrmann E, Zeuzem S, Cakaloglu Y, Karayalcin S, Flisiak R, van' t Veen A, de Man RA, Schalm SW, Janssen HL, Haagmans BL; HBV 99-01 Study Group.

Antivir Ther. 2007;12(8):1285-94.

PMID:
18240868
8.

Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection.

Lurie Y, Rouzier-Panis R, Webster GJ, Dusheiko GM, Laughlin M, Jackson ML, Oren R.

Clin Gastroenterol Hepatol. 2005 Jun;3(6):610-5.

PMID:
15952104
9.

Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C.

Jen JF, Glue P, Ezzet F, Chung C, Gupta SK, Jacobs S, Hajian G.

Clin Pharmacol Ther. 2001 Jun;69(6):407-21.

PMID:
11406738
10.

Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.

Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver RT, Tendler C; PEG-Intron CML Study Group.

Leukemia. 2004 Feb;18(2):309-15.

PMID:
14671645
12.

Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

Jen JF, Glue P, Gupta S, Zambas D, Hajian G.

Ther Drug Monit. 2000 Oct;22(5):555-65.

PMID:
11034261
13.

Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

Talpaz M, O'Brien S, Rose E, Gupta S, Shan J, Cortes J, Giles FJ, Faderl S, Kantarjian HM.

Blood. 2001 Sep 15;98(6):1708-13.

14.
15.

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.

Garcia-Manero G, Talpaz M, Giles FJ, Cortes J, Faderl S, O'Brien S, Thomas D, Verstovsek S, Beth Rios M, Shan J, Ferrajoli A, Wierda W, Kantarjian HM.

Cancer. 2003 Jun 15;97(12):3010-6.

16.

Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia.

Lipton JH, Khoroshko N, Golenkov A, Abdulkadyrov K, Nair K, Raghunadharao D, Brummendorf T, Yoo K, Bergstrom B; Pegasys CML Study Group.

Leuk Lymphoma. 2007 Mar;48(3):497-505.

PMID:
17454589
17.

Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.

Asahina Y, Izumi N, Umeda N, Hosokawa T, Ueda K, Doi F, Tsuchiya K, Nakanishi H, Matsunaga K, Kitamura T, Kurosaki M, Uchihara M, Higaki M, Miyake S.

J Viral Hepat. 2007 Jun;14(6):396-403.

PMID:
17501760
18.

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.

Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, Purdum PP 3rd, Jensen D, Smith C, Lee WM, Boyer TD, Lin A, Pedder S, DePamphilis J.

Hepatology. 2001 Feb;33(2):433-8.

PMID:
11172346
19.

Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.

El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, El-Nakeeb A, Selim O, Saied A.

Am J Gastroenterol. 2005 Nov;100(11):2447-52.

PMID:
16279899

Supplemental Content

Support Center